TABLE 1.
GenBank no. | Gene name | Nonpolarized
|
Polarized, GCOS (FC) | |||
---|---|---|---|---|---|---|
GCOS (FC) | SAM (FC) | Spotfire (FC) | ANOVA (P) | |||
Apoptosis | ||||||
BF594446 | Myeloid cell leukemia sequence 1 (Bcl-2-related) | 2.6 | 2.7 | 2.6 | 0.013611 | 5.3 |
NM_021960.1 | Myeloid cell leukemia sequence 1 (Bcl-2-related) | 2.5 | 2.5 | 2.3 | 0.018607 | 4 |
BF981280 | Myeloid cell leukemia sequence 1 (Bcl-2-related) | 2.4 | 3.2 | 3.0 | 0.001319 | 1.9 |
AI275690 | Myeloid cell leukemia sequence 1 (Bcl-2-related) | 2.1 | 2.4 | 2.3 | 0.014808 | 2.8 |
NM_007350.1 | TDAG51 | 5.5 | 6.2 | 6.4 | 0.01555 | 3 |
AI795908 | TDAG51 | 4.7 | 4.8 | 4.6 | 0.00381 | 4 |
AA576961 | TDAG51 | 4.3 | 4.3 | 4.1 | 0.008432 | 4 |
NM_007350.1 | TDAG51 | 2 | 2.2 | 2.2 | 0.007025 | 1.6 |
Cellular reorganization | ||||||
AF099730 | Gap junction protein, beta 3 (connexin 31) | 2.3 | 2.1 | 2.1 | 7.66E-06 | 2.1 |
BF060667 | Gap junction protein, beta 3 (connexin 31) | 2.2 | 2.1 | 2.2 | 1.15E-06 | 2.3 |
Z19574 | Cytokeratin 17 | 2.2 | 2.4 | 2.5 | 5.31E-20 | NS |
BG054844 | Ras homolog gene family, member E (RhoE) | 2.2 | 2.1 | 2.1 | 0.001669 | 1.6 |
Cell growth/Differentiation/Cell cycle regulation | ||||||
NM_000389.1 | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 3.1 | 2.3 | 2.3 | 0.002638 | 3.2 |
NM_012242.1 | Dickkopf homolog 1 (DKK1) | 2.8 | 2.7 | 2.6 | 0.000874 | NS |
NM_001432.1 | Epiregulin | 2.7 | 2.9 | 2.8 | 0.012219 | 2.1 |
AF003934.1 | Growth differentiation factor 15 (GDF15) | 2.3 | 2.2 | 2.5 | 0.008893 | NS |
U77914.1 | Jagged 1 (JAG1) | 2.2 | 2.5 | 2.5 | 0.000286 | 1.7 |
U61276.1 | Jagged 1 (JAG1) | 2.1 | 2 | 2.1 | 6.33E-05 | 1.9 |
U73936.1 | Jagged 1 (JAG1) | 2.1 | 2.5 | 2.5 | 0.000304 | 1.7 |
NM_002467.1 | Myc proto-oncogene protein (c-Myc) | 2.1 | 2.3 | 2.2 | 0.013804 | 1.5 |
AF045451.1 | NGFI-A binding protein 1 (Nab1) | 3 | 3.3 | 3.3 | 0.015786 | 1.7 |
NM_002607.1 | Platelet-derived growth factor alpha polypeptide | 2.4 | 2.3 | 2.2 | 0.006248 | 1.5 |
AI263909 | Ras homolog gene family, member B (RhoB) | 2.7 | 2.9 | 2.8 | 0.001791 | 3.2 |
NM_023925.1 | C1q domain containing 1 | 2.1 | 2 | 2.0 | 0.004791 | 2 |
Cytokines | ||||||
NM_013246.1 | Cardiotrophin-like cytokine; neurotrophin-1B-cell stimulating factor-3 (CLC) | 2.5 | 2.3 | 2.6 | 0.00929 | 2.6 |
NM_001511.1 | GRO1 oncogene | 3.1 | 4.2 | 4.4 | 0.00368 | NS |
AF043337.1 | IL-8 | 31.6 | 24.3 | 32.9 | 0.006866 | 1.9 |
NM_000584.1 | IL-8 | 26.4 | 23.8 | 21.8 | 0.010181 | 3 |
NM_002309.2 | Leukemia inhibitory factor (LIF) | 2.5 | 2.7 | 2.8 | 0.007476 | 2.3 |
Extracellular matrix digestion | ||||||
NM_002421.2 | Matrix metalloproteinase 1 (MMP1)b | 4 | 4.5 | 4.0 | 0.035324 | 2.6 |
AY029180.1 | Soluble urokinase plasminogen activator receptor | 2.1 | 2.4 | 2.3 | 0.006765 | 1.9 |
U08839.1 | Urokinase-type plasminogen activator receptor | 2 | 2 | 2.0 | 0.022107 | 1.7 |
Signal transduction | ||||||
U16996.1 | Dual specificity protein phosphatase 5 | 2.1 | 2 | 2.0 | 0.00587 | 4 |
NM_004431.1 | Ephrin type-A receptor 2 (EphA2) | 2.7 | 3.1 | 3.0 | 0.006323 | 2.6 |
U16797.1 | Ephrin-B2 | 2.6 | 2.2 | 2.3 | 0.005556 | 2.8 |
BF001670 | Ephrin-B2 | 2.1 | 2.1 | 2.2 | 0.006585 | 2.5 |
NM_002923.1 | Regulator of G-protein signaling 2 (RGS2) | 4.2 | 3.8 | 3.6 | 0.005268 | 2.8 |
Transcription factors | ||||||
AL564683 | CCAAT enhancer binding protein (CEBP), beta | 2 | 2.1 | 2.0 | 0.029667 | 3.2 |
BG251266 | Fra-1 | 5.2 | 5.3 | 5.9 | 0.001552 | 12.1 |
AL021977 | MAFF-like protein | 3.2 | 2.7 | 3.3 | 0.003684 | 1.7 |
NM_014755.1 | SERTA domain containing 2 | 2 | 2 | 2.0 | 0.018674 | 2 |
Other/unknown | ||||||
NM_025047.1 | ADP-ribosylation factor 2 (cDNA, 79%) | 2.3 | 2.6 | 2.5 | 0.000746 | NSc |
NM_000693.1 | Aldehyde dehydrogenase 1 family, member A3 | 2.4 | 2.6 | 2.4 | 0.04679 | 2.1 |
NM_006033.1 | Endothelial lipase | 2.7 | 3.2 | 2.9 | 0.023085 | 1.6 |
NM_001450.1 | LIM-protein 3 | 2.2 | 2.3 | 2.2 | 0.009135 | 1.6 |
FC, fold change. Genes listed twice were represented on the microarrays by more than one probe set, and each was determined separately to be significantly upregulated by Act.
Also upregulated between 0 and 12 h, as determined by all four analysis techniques.
NS, no significant change.